The lancet. Psychiatry

Links between GLP-1 receptor drugs and hospital stays for alcohol and drug problems during and after treatment

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

GLP-1 receptor agonists may reduce substance use across different disorders.

  • Evidence indicates a potential link between GLP-1 receptor agonists and reduced substance use.
  • No data currently exist on substance use-related outcomes after stopping GLP-1 treatment.
  • The investigation focuses on the risk of alcohol and substance use-related hospitalizations during and after GLP-1 exposure.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declaration of interests JF and JW declare support for the current study as applicants for grants awarded by Forte (2020-00467), Karolinska Institutet (KID, 2020-02653), and Region Stockholm (FoUI-977024 and 2020-02653). PB declares travel support for the current study by the German Center for Mental Health, Mannheim-Heidelberg-Ulm site. All other authors declare no competing interests.
PubMed

Related papers

May '26
Kidney health with GLP-1 drugs in people with type 2 diabetes already taking SGLT2 inhibitors
journal article
Mar '26
Use of GLP-1 receptor drugs linked to worsening mental health in people with depression and anxiety in Sweden
top 1% journal
cited by 4 papers
journal article
May '25
Stopping treatment with two diabetes drug types in a national group of people with type 2 diabetes
top 2% journal
cited by 12 papers
journal article
Sep '24
How frailty affects the safety and effectiveness of two diabetes drugs in people with type 2 diabetes in Taiwan
top 1% journal
cited by 20 papers
comparative study
Feb '25
GLP-1 receptor drugs for people with diabetes and long-term kidney disease
cited by 10 papers
systematic review
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Feb '25
Risk of suicidal thoughts in type 2 diabetes patients starting glucagon-like peptide-1 receptor drugs compared to other treatments
top 5% journal
cited by 33 papers
journal article
Mar '26
Glucagon-like peptide-1 drugs and risk of substance use disorders in US veterans with type 2 diabetes
top 5% journal
cited by 4 papers
journal article

Featured in

GLP-1 TherapiesGLP-1 TherapiesIssue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
yesterday7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
1 week ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
2 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
3 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
4 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
5 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
6 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
7 weeks ago7 studies
issue #38
Two-thirds of patients kept weight off after stopping GLP-1 drugs
8 weeks ago7 studies
issue #36
Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief